← All trials
NCT04716725
Phase 2Interventional
Includes controlled clinical studies conducted to evaluate the effectiveness of the drug for a particular indication or indications in participants with the disease or condition under study and to determine the common short-term side effects and risks.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Sep 28, 2021
- Primary completion
- Dec 31, 2023
- Completion date
- Dec 31, 2024
- First posted
- Jan 20, 2021
- Last posted
- Oct 1, 2021
- Enrollment
- 100
- Arms / groups
- 1 / —
- Source
- AACT · ingestion pipeline
Sponsors
- University of California, San FranciscoLead sponsor
- University of California, San FranciscoReponsible party - principal investigator
- University of California, San FranciscoOverall official - principal investigator
- Gateway for Cancer ResearchCollaborator
- Conquer Cancer FoundationCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.